Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 18/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508874 | 0.88 | PPARG (0.47) | FOLH1 | |
| SCHEMBL5051236 | 0.87 | FOLH1 (0.74) | FOLH1 | |
| SCHEMBL5057905 | 0.87 | FOLH1 (0.46) | FOLH1 | |
| SCHEMBL14508887 | 0.82 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL5053104 | 0.81 | FOLH1 (0.65) | FOLH1 | |
| SCHEMBL5054541 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL5054563 | 0.81 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL5057981 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL5060115 | 0.80 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL5051176 | 0.78 | FOLH1 (0.61) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-6586623-B2 | Carbocyclic mercaptans such as 3-carboxy-alpha-(3-mercapto-propyl) benzenepropanoic acid, used as N-acetylated alpha-linked acidic dipeptidase(NAALADase) inhibitors and for medical diadnosis | GUILFORD PHARMACEUTICALS INC. | 2003-07-01 | — | — | US | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-7968593-B2 | Thiolactones | EISAI INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100048667-A1 | Thiolactones | EISAI INC. | 2010-02-25 | — | — | US | disclosed |
| US-7553866-B2 | 3-(2-Oxo-tetrahydrothiopyran-3-yl)propionic acid; inhibiting the prostrate specific antigen;angiogenesis inhibition; compulsive disorder, neuropathy, analgesics, anticarcinogenic agents; Huntinton's disease; antidiabetic agents; retinopathy; gluacoma; effecting transforming growth factor, glutamate | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1599461-B1 | THIOLACTONES AS NAALADase INHIBITORS | EISAI CORP NORTH AMERICA (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| EP-1988088-A1 | Thiolactones | GUILFORD PHARMACEUTICALS INC. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| WO-2002096866-A2 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002092553-A1 | HYDROXAMIC ACIDS AND ACYL HYDROXAMINES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | FOLH1 432/4885 |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885 |
| US-20100048667-A1 | Thiolactones | RIMKLA, ALDH1A2, GGT1 | FOLH1 9/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.